Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Símbolo de cotizaciónNXL
Nombre de la empresaNexalin Technology Inc
Fecha de salida a bolsaSep 16, 2022
Director ejecutivoMr. Mark White
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 16
Dirección1776 Yorktown
CiudadHOUSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77056
Teléfono18322600222
Sitio Webhttps://nexalin.com
Símbolo de cotizaciónNXL
Fecha de salida a bolsaSep 16, 2022
Director ejecutivoMr. Mark White
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos